Provided by Tiger Trade Technology Pte. Ltd.

Iovance Biotherapeutics, Inc.

5.41
+0.28005.46%
Post-market: 5.410.00000.00%19:59 EDT
Volume:27.55M
Turnover:147.00M
Market Cap:2.23B
PE:-4.94
High:5.63
Open:5.02
Low:5.01
Close:5.13
52wk High:5.63
52wk Low:1.64
Shares:411.96M
Float Shares:339.00M
Volume Ratio:1.15
T/O Rate:8.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0941
EPS(LYR):-1.0941
ROE:-55.50%
ROA:-27.30%
PB:3.19
PE(LYR):-4.94

Loading ...

May 09, 2024

Major Issues Report

Form 8-K - Current report
Apr 03, 2024

Major Issues Report

Form 8-K - Current report
Mar 29, 2024

Major Issues Report

Form 8-K - Current report
Mar 19, 2024

Beneficial Ownership Change

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
Mar 04, 2024

Major Issues Report

Form 8-K - Current report
Mar 01, 2024

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 29, 2024

Major Issues Report

Form 8-K - Current report
Feb 29, 2024

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 28, 2024

Major Issues Report

Form 8-K - Current report
Feb 22, 2024

Major Issues Report

Form 8-K - Current report
Feb 20, 2024

Major Issues Report

Form 8-K - Current report
Feb 20, 2024

Major Issues Report

Form 8-K - Current report
Feb 14, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Feb 14, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Feb 14, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Feb 09, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Jan 26, 2024

Major Issues Report

Form 8-K - Current report
Jan 09, 2024

Major Issues Report

Form 8-K - Current report
Dec 27, 2023

Major Issues Report

Form 8-K - Current report
Nov 18, 2023

Correspondence

Form CORRESP - Correspondence